Longhua Sun
Agricultural and Biological Sciences · Indiana University
Publications
78
Citations
1,622
Est. group size
~7
Recurring co-author estimate
Active years
29
Publishing since 1998
Longhua Sun's recent research focuses on lung cancer, particularly non-small cell lung cancer (NSCLC) and lung adenocarcinoma. The work spans clinical trials of new drugs (such as antibody-drug conjugates and targeted therapies), laboratory studies of the molecular pathways that drive cancer growth, and the development of diagnostic methods for detecting cancer markers. Studies often examine how specific proteins and signaling pathways influence tumor progression and treatment response.
Publication activity has been fairly steady over the past decade with a notable increase in the most recent years, peaking in 2025.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Genomic Copy Number Variation Profiling of Pleural Effusion cfDNA via LP-WGS for Precision Diagnosis and Prognostic Stratification in Lung Adenocarcinoma-associated Malignant Pleural Effusion running title: cfDNA CNV for LUAD-MPE Diagnosis and Prognosis
Research Square · 2026
- Sacituzumab tirumotecan versus docetaxel for previously treated <i>EGFR</i> -mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial
BMJ · 2025
- Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
The Lancet · 2025
- Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study.
Journal of Clinical Oncology · 2025
- Ginkgetin inhibits the proliferation and migration of lung cancer cells via FAK/STAT3/AKT pathway
Molecular Biology Reports · 2025
- Phase 1 study of SHR-1826, a c-MET–directed antibody-drug-conjugate (ADC), in advanced solid tumors.
Journal of Clinical Oncology · 2025
- CRTC1 enhances PD-L1-mediated tumor immunosuppression in non-small cell lung cancer via the Notch1/Akt signaling pathway
Frontiers in Immunology · 2025
- Results from a phase 1/2 study of 7MW3711: A novel B7-H3 antibody-drug conjugate (ADC) incorporating a topoisomerase I inhibitor in patients with lung cancer.
Journal of Clinical Oncology · 2025
- Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study
Journal of Thoracic Oncology · 2025
- Evodiamine Suppresses Lung Cancer Progression Through Modulating FAK/STAT3/AKT Signaling Pathway
The American Journal of Chinese Medicine · 2025
- An innovative technique for sensitive detection of carcinoembryonic antigen as a cell lung cancer marker
Research Square · 2025
- MA04.07 A Phase 2 Multicenter Umbrella Trial Assessing Tislelizumab ± Anti-TIGIT or Anti-LAG-3 mAb ± Chemotherapy in Resectable NSCLC
Journal of Thoracic Oncology · 2025
- Sensitive chemiluminescent determination of CYFRA 21–1 as a lung cancer marker using PVP/NiO-supported luminol@ZIF-67-aptamer composite
Microchimica Acta · 2025
- Interplay between acetylation and ubiquitination controls PSAT1 protein stability in lung adenocarcinoma
Communications Biology · 2024
- Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I study
European Journal of Cancer · 2024
- Journal of Clinical Oncology×3
- Pathogens×3
- Insects×3
- Research Square×3
- Nature Communications×2
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile